Key result
Pathological response after chemotherapy trends toward better survival, whereas radiological response matters more after radiotherapy.
Why the study?
To explore the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma.
Does pathological response (residual visible tumor) versus radiological response (RECIST) better predict survival outcomes in patients with primary localized MFS and UPS treated with neoadjuvant therapies?
Cohort (n=693)
No
Does pathological response (residual visible tumor) versus radiological response (RECIST) better predict survival outcomes in patients with primary localized MFS and UPS treated with neoadjuvant therapies?
Pathological response (residual visible tumor) is a more relevant prognostic factor than radiological size reduction after neoadjuvant chemotherapy, whereas radiological response is more relevant after neoadjuvant radiotherapy or chemoradiotherapy in MFS and UPS.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: To explore the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS). METHODS: All consecutive patients with primary localized MFS and UPS of the extremities and trunk wall surgically treated with curative intent at our center (2005-2021) were included. Clinical data including residual visible tumor (VT%) on surgical specimen and Response Evaluation Criteria in Solid Tumor (RECIST) were retrieved. Kaplan-Meier curves for overall survival and disease-free survival, and cumulative incidence of local relapse and distant metastasis were estimated in a competing risk framework according to RECIST and VT%, overall and by treatment group. Cox and Fine and Gray multivariable models were performed. RESULTS: Of 693 patients affected by primary MFS and UPS, 233 (66 MFS and 167 UPS) were treated by neoadjuvant chemotherapy (naChT), radiotherapy (naRT), or both (naChT-RT). VT% was ≤5% in 13/46 (28.2%), 24/99 (24.2%), and 40/88 (45.4%) patients, respectively. There were 11/46 (29.7%), 22/99 (22.7%), and 23/88 (26.1%) RECIST partial responses and 18/46 (48.6%), 59/99 (60.8%), and 60/88 (68.2%) RECIST stable disease, respectively. In naChT, a trend for a better survival was observed when VT% ≤5% (p = .09), whereas RECIST partial responses and stable disease had the same outcome. VT% was not associated with outcome in naRT or naChT-RT, whereas RECIST response was. CONCLUSION: In primary localized MFS and UPS treated with neoadjuvant therapies, VT% seems more relevant than size reduction after naChT, whereas the opposite is true when naRT is administered alone or concurrent to ChT.
Answers are grounded in this paper and cite their sources.
Pathological response may aid chemotherapy assessment in localized MFS/UPS; leaves open optimal metrics after radiotherapy.
No takes yet. Share an insight, caveat, or question.
Danieli et al. (2023) conducted a cohort in Primary localized myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (n=693). Neoadjuvant chemotherapy, radiotherapy, or both was evaluated on Correlation between pathological (residual visible tumor) and radiological (RECIST) response and survival outcomes (p=0.09). Pathological response trended toward better survival after neoadjuvant chemotherapy for MFS and UPS, whereas radiological response was more relevant after radiotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: